1. Gupta S, Jawanda MK. Oral Lichen Planus: An Update on Etiology, Pathogenesis, Clinical Presentation, Diagnosis and Management. Indian J Dermatol. 2015;60:222-9.

https://doi.org/10.4103/0019-5154.156315

PMid:26120146 PMCid:PMC4458931

2. Gonzalez-Moles MA, Warnakulasuriya S, Gonzalez-Ruiz I, Gonzalez-Ruiz L, Ayen A, Lenouvel D, et al. Worldwide prevalence of oral lichen planus: A systematic review and meta-analysis. Oral Dis. 2021;27:813-28.

https://doi.org/10.1111/odi.13323

PMid:32144836 

3. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46:207-14.

https://doi.org/10.1067/mjd.2002.120452

PMid:11807431 

4. Lodi G, Manfredi M, Mercadante V, Murphy R, Carrozzo M. Interventions for treating oral lichen planus: corticosteroid therapies. Cochrane Database Syst Rev. 2020;2:CD001168.

https://doi.org/10.1002/14651858.CD001168.pub3

PMid:32108333 

5. Idrees M, Kujan O, Shearston K, Farah CS. Oral lichen planus has a very low malignant transformation rate: A systematic review and meta-analysis using strict diagnostic and inclusion criteria. J Oral Pathol Med. 2021;50:287-98.

https://doi.org/10.1111/jop.12996

PMid:31981238 

6. Warnakulasuriya S, Lodi G. Oral potentially malignant disorders: Proceedings from an expert symposium. Oral Dis. 2021;27:1859-61.

https://doi.org/10.1111/odi.13999

PMid:34379867 

7. Gonzalez-Moles MA, Warnakulasuriya S, Gonzalez-Ruiz I, Ayen A, Gonzalez-Ruiz L, Ruiz-Avila I, et al. Dysplasia in oral lichen planus: relevance, controversies and challenges. A position paper. Med Oral Patol Oral Cir Bucal. 2021;26:e541-e8.

https://doi.org/10.4317/medoral.24610

PMid:34162824 PMCid:PMC8254877

8. van der Meij EH, Schepman KP, Plonait DR, Axell T, van der Waal I. Interobserver and intraobserver variability in the clinical assessment of oral lichen planus. J Oral Pathol Med. 2002;31:95-8.

https://doi.org/10.1046/j.0904-2512.2001.00174.x

PMid:11896830 

9. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights. 2010;5:9-20.

https://doi.org/10.4137/BMI.S2185

PMid:20212918 PMCid:PMC2832341

10. Teunissen CE, Malekzadeh A, Leurs C, Bridel C, Killestein J. Body fluid biomarkers for multiple sclerosis--the long road to clinical application. Nat Rev Neurol. 2015;11:585-96.

https://doi.org/10.1038/nrneurol.2015.173

PMid:26392381 

11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

https://doi.org/10.1136/bmj.b2700

PMid:19622552 PMCid:PMC2714672

12. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2.

https://doi.org/10.1186/2046-4053-1-2

PMid:22587842 PMCid:PMC3348673

13. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.

https://doi.org/10.1371/journal.pmed.1001216

PMid:22675273 PMCid:PMC3362085

14. Mattila R, Alanen K, Syrjanen S. Desmocollin expression in oral atrophic lichen planus correlates with clinical behavior and DNA content. J Cutan Pathol. 2008;35:832-8.

https://doi.org/10.1111/j.1600-0560.2007.00903.x

PMid:18422976 

15. Schifter M, Jones AM, Walker DM. Epithelial p53 gene expression and mutational analysis, combined with growth fraction assessment, in oral lichen planus. J Oral Pathol Med. 1998;27:318-24.

https://doi.org/10.1111/j.1600-0714.1998.tb01963.x

PMid:9725569 

16. Valente G, Pagano M, Carrozzo M, Carbone M, Bobba V, Palestro G, et al. Sequential immunohistochemical p53 expression in biopsies of oral lichen planus undergoing malignant evolution. J Oral Pathol Med. 2001;30:135-40.

https://doi.org/10.1034/j.1600-0714.2001.300302.x

PMid:11271627 

17. Ogmundsdottir HM, Hilmarsdottir H, Astvaldsdottir A, Johannsson JH, Holbrook WP. Oral lichen planus has a high rate of TP53 mutations. A study of oral mucosa in icelanD. Eur J Oral Sci. 2002;110:192-8.

https://doi.org/10.1034/j.1600-0447.2002.21235.x

PMid:12120703 

18. Lee JJ, Kuo MY, Cheng SJ, Chiang CP, Jeng JH, Chang HH, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:471-8.

https://doi.org/10.1016/j.tripleo.2004.10.018

PMid:15772596 

19. de Sousa FA, Paradella TC, Carvalho YR, Rosa LE. Comparative analysis of the expression of proliferating cell nuclear antigen, p53, bax, and bcl-2 in oral lichen planus and oral squamous cell carcinoma. Ann Diagn Pathol. 2009;13:308-12.

https://doi.org/10.1016/j.anndiagpath.2009.06.001

PMid:19751907 

20. Safadi RA, Al Jaber SZ, Hammad HM, Hamasha AA. Oral lichen planus shows higher expressions of tumor suppressor gene products of p53 and p21 compared to oral mucositis. An immunohistochemical study. Arch Oral Biol. 2010;55:454-61.

https://doi.org/10.1016/j.archoralbio.2010.03.019

PMid:20427035 

21. Leyva-Huerta ER, Ledesma-Montes C, Rojo-Botello RE, Vega-Memije E. P53 and bcl-2 immunoexpression in patients with oral lichen planus and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2012;17:e745-50.

https://doi.org/10.4317/medoral.18013

PMid:22549684 PMCid:PMC3482516

22. Oliveira Alves M, Balducci I, Rodarte Carvalho Y, Cabral L, Nunes F, Almeida J. Evaluation of the expression of p53, MDM2, and SUMO-1 in oral lichen planus. Oral Dis. 2013;19:775-80.

https://doi.org/10.1111/odi.12068

PMid:23350884 

23. Sanketh DS, Kumari K, Rao RS, Haragannavar VC, Sarode SC, Sarode GS, et al. Expression of Ki-67, p53, alpha-SMA and COX-2 in lichen planus and related lesions: A pilot study. J Oral Biol Craniofac Res. 2019;9:230-5.

https://doi.org/10.1016/j.jobcr.2018.02.003

PMid:31211042 PMCid:PMC6562184

24. Shailaja G, Kumar JV, Baghirath PV, Kumar U, Ashalata G, Krishna AB. Estimation of malignant transformation rate in cases of oral epithelial dysplasia and lichen planus using immunohistochemical expression of Ki-67, p53, BCL-2, and BAX markers. Dent Res J (Isfahan). 2015;12:235-42.

PMid:26005463

25. Hadzi-Mihailovic M, Cakic S, Jankovic S, Raybaud H, Nedeljkovic N, Jankovic L. Ki-67 expression in oral lichen planus. J BUON. 2012;17:132-7.

PMid:22517707

26. Rosa EA, Hurtado-Puerto AM, Falcao DP, Brietzke AP, De Almeida Prado Franceschi LE, Cavalcanti Neto FF, et al. Oral lichen planus and malignant transformation: The role of p16, Ki-67, Bub-3 and SOX4 in assessing precancerous potential. Exp Ther Med. 2018;15:4157-66.

https://doi.org/10.3892/etm.2018.5971

PMid:29731815 PMCid:PMC5920964

27. Zargaran M, Jamshidi S, Eshghyar N, Moghimbeigi A. Suitability/unsuitability of cell proliferation as an indicator of malignant potential in oral lichen planus: an immunohistochemical study. Asian Pac J Cancer Prev. 2013;14:6979-83.

https://doi.org/10.7314/APJCP.2013.14.11.6979

PMid:24377636 

28. Hadzi-Mihailovic M, Raybaud H, Monteil R, Cakic S, Djuric M, Jankovic L. Bcl-2 expression and its possible influence on malignant transformation of oral lichen planus. J BUON. 2010;15:362-8.

PMid:20658736

29. Nafarzadeh S, Jafari S, Bijani A. Assessment of bax and bcl-2 immunoexpression in patients with oral lichen planus and oral squamous cell carcinoma. Int J Mol Cell Med. 2013;2:136-42.

PMid:24551804

30. Goel S, Khurana N, Marwah A, Gupta S. Expression of cdk4 and p16 in Oral Lichen Planus. J Oral Maxillofac Res. 2015;6:e4.

https://doi.org/10.5037/jomr.2015.6204

PMid:26229583 PMCid:PMC4516856

31. Salehinejad J, Sharifi N, Amirchaghmaghi M, Ghazi N, Shakeri MT, Ghazi A. Immunohistochemical expression of p16 protein in oral squamous cell carcinoma and lichen planus. Ann Diagn Pathol. 2014;18:210-3

https://doi.org/10.1016/j.anndiagpath.2014.03.009

PMid:24850170 

32. Liu T, Zhang H, Yang X, Li X, Shi Y, Niu W, et al. Study on expression of p16 and human papillomavirus 16 and 18 (E6) in OLP and its malignant transformation. Pathol Res Pract. 2018;214:296-302.

https://doi.org/10.1016/j.prp.2017.09.014

PMid:29254790 

33. Hadzi-Mihailovic M, Stanimirovic D, Pasoski B. Role of tumor suppressor protein p16 in patients with oral lichen planus. J BUON. 2020;25:1193-8.

PMid:32521925

34. Neppelberg E, Johannessen AC. DNA content, Cyclooxygenase-2 expression and loss of E-cadherin expression do not predict risk of malignant transformation in oral lichen planus. Eur Arch Otorhinolaryngol. 2007;264:1223-30.

https://doi.org/10.1007/s00405-007-0346-5

PMid:17530268 

35. Baghaei F, Shojaei S, Afshar-Moghaddam N, Zargaran M, Rastin V, Nasr M, et al. Study of P21 Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma by Immunohistochemical Technique. J Dent (Shiraz). 2015;16:156-61.

PMid:26331143

36. Oluwadara O, Giacomelli L, Christensen R, Kossan G, Avezova R, Chiappelli F. LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma. Bioinformation. 2009;4:249-57.

https://doi.org/10.6026/97320630004248

PMid:20975919 PMCid:PMC2951717

37. Suganya G, Bavle RM, Paremala K, Makarla S, Sudhakar M, Reshma V. Survivin expression in oral lichen planus: Role in malignant transformation. J Oral Maxillofac Pathol. 2016;20:234-8.

https://doi.org/10.4103/0973-029X.185912

PMid:27601815 PMCid:PMC4989553

38. Speight PM, Takata T. New tumour entities in the 4th edition of the World Health Organization Classification of Head and Neck tumours: odontogenic and maxillofacial bone tumours. Virchows Arch. 2018;472:331-9.

https://doi.org/10.1007/s00428-017-2182-3

PMid:28674741 PMCid:PMC5886999

39. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400-14.

https://doi.org/10.1038/nrc2657

PMid:19440234 PMCid:PMC2722839

40. McCormick D, Hall PA. The complexities of proliferating cell nuclear antigen. Histopathology. 1992;21:591-4.

https://doi.org/10.1111/j.1365-2559.1992.tb00454.x

PMid:1361482 

41. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002;179:1-14.

https://doi.org/10.1016/S0304-3835(01)00847-3

PMid:11880176

42. Huang WY, Coltrera M, Schubert M, Morton T, Truelove E. Histopathologic evaluation of proliferating cell nuclear antigen (PC10) in oral epithelial hyperplasias and premalignant lesions. Oral Surg Oral Med Oral Pathol. 1994;78:748-54.

https://doi.org/10.1016/0030-4220(94)90091-4

PMid:7534896

43. Poosarla C, Ramesh M, Ramesh K, Gudiseva S, Bala S, Sundar M. Proliferating Cell Nuclear Antigen in Premalignancy and Oral Squamous Cell Carcinoma. J Clin Diagn Res. 2015;9:ZC39-41.

https://doi.org/10.7860/JCDR/2015/12645.6094

PMid:26266215 PMCid:PMC4525605

44. Tsushima F, Sakurai J, Uesugi A, Oikawa Y, Ohsako T, Mochizuki Y, et al. Malignant transformation of oral lichen planus: a retrospective study of 565 Japanese patients. BMC Oral Health. 2021;21:298.

https://doi.org/10.1186/s12903-021-01652-7

PMid:34112142 PMCid:PMC8194014

45. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-25.

https://doi.org/10.1016/0092-8674(93)90500-P

PMid:8242752

46. Yanamoto S, Kawasaki G, Yoshitomi I, Mizuno A. p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:593-600.

https://doi.org/10.1067/moe.2002.127404

PMid:12424454 

47. Gonzalez-Moles MA, Bascones-Ilundain C, Gil Montoya JA, Ruiz-Avila I, Delgado-Rodriguez M, Bascones-Martinez A. Cell cycle regulating mechanisms in oral lichen planus: molecular bases in epithelium predisposed to malignant transformation. Arch Oral Biol. 2006;51:1093-103.

https://doi.org/10.1016/j.archoralbio.2006.06.007

PMid:16914114 

48. Wang L, Han H, Dong L, Wang Z, Qin Y. Function of p21 and its therapeutic effects in esophageal cancer. Oncol Lett. 2021;21:136.

https://doi.org/10.3892/ol.2020.12397

PMid:33552255 PMCid:PMC7798030

49. Monteiro L, Mello FW, Warnakulasuriya S. Tissue biomarkers for predicting the risk of oral cancer in patients diagnosed with oral leukoplakia: A systematic review. Oral Dis. 2021;27:1977-92.

https://doi.org/10.1111/odi.13747

PMid:33290585 

50. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233-40.

https://doi.org/10.1038/35106009

PMid:11902578 

51. Graveland AP, Bremmer JF, de Maaker M, Brink A, Cobussen P, Zwart M, et al. Molecular screening of oral precancer. Oral Oncol. 2013;49:1129-35.

https://doi.org/10.1016/j.oraloncology.2013.09.005

PMid:24120275 

52. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med. 1995;332:712-7.

https://doi.org/10.1056/NEJM199503163321104

PMid:7854378 

53. Kuttan NA, Rosin MP, Ambika K, Priddy RW, Bhakthan NM, Zhang L. High prevalence of expression of p53 oncoprotein in oral carcinomas from India associated with betel and tobacco chewing. Eur J Cancer B Oral Oncol. 1995;31B:169-73.

https://doi.org/10.1016/0964-1955(94)00051-5

PMid:7549756

54. Kilpi A, Rich AM, Konttinen YT, Reade PC. Expression of c-erbB-2 protein in keratinocytes of oral mucosal lichen planus and subsequent squamous cell carcinoma. Eur J Oral Sci. 1996;104:278-84.

https://doi.org/10.1111/j.1600-0722.1996.tb00078.x

PMid:8831062 

55. Saluja TS, Ali M, Mishra P, Kumar V, Singh SK. Prognostic Value of Cancer Stem Cell Markers in Potentially Malignant Disorders of Oral Mucosa: A Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2019;28:144-53

https://doi.org/10.1158/1055-9965.EPI-18-0672

PMid:30315141